Current Role of Delta Radiomics in Head and Neck Oncology.

adaptive treatment chemotherapy outcome prediction radiomics radiotherapy sequential imaging

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Jan 2023
Historique:
received: 27 11 2022
accepted: 19 01 2023
entrez: 11 2 2023
pubmed: 12 2 2023
medline: 15 2 2023
Statut: epublish

Résumé

The latest developments in the management of head and neck cancer show an increasing trend in the implementation of novel approaches using artificial intelligence for better patient stratification and treatment-related risk evaluation. Radiomics, or the extraction of data from various imaging modalities, is a tool often used to evaluate specific features related to the tumour or normal tissue that are not identifiable by the naked eye and which can add value to existing clinical data. Furthermore, the assessment of feature variations from one time point to another based on subsequent images, known as delta radiomics, was shown to have even higher value for treatment-outcome prediction or patient stratification into risk categories. The information gathered from delta radiomics can, further, be used for decision making regarding treatment adaptation or other interventions found to be beneficial to the patient. The aim of this work is to collate the existing studies on delta radiomics in head and neck cancer and evaluate its role in tumour response and normal-tissue toxicity predictions alike. Moreover, this work also highlights the role of holomics, which brings under the same umbrella clinical and radiomic features, for a more complex patient characterization and treatment optimisation.

Identifiants

pubmed: 36768535
pii: ijms24032214
doi: 10.3390/ijms24032214
pmc: PMC9916410
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Phys Med Biol. 2019 May 23;64(11):115004
pubmed: 30844784
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1319-1329
pubmed: 30003997
Eur J Nucl Med Mol Imaging. 2014 May;41(5):915-24
pubmed: 24346414
J Pers Med. 2021 Oct 26;11(11):
pubmed: 34834445
Phys Imaging Radiat Oncol. 2022 Nov 04;24:95-101
pubmed: 36386445
Eur Radiol. 2021 Feb;31(2):616-628
pubmed: 32851444
Int J Mol Sci. 2018 Aug 24;19(9):
pubmed: 30149561
Front Oncol. 2021 May 27;11:664304
pubmed: 34123824
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1056-1064
pubmed: 31773233
PLoS One. 2019 Mar 28;14(3):e0214299
pubmed: 30921388
Front Artif Intell. 2021 Apr 09;4:618469
pubmed: 33898983
Future Sci OA. 2020 Sep 04;6(9):FSO624
pubmed: 33235811
Quant Imaging Med Surg. 2021 Dec;11(12):4781-4796
pubmed: 34888189
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1101-1110
pubmed: 28939226
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
Life (Basel). 2022 May 12;12(5):
pubmed: 35629389
Sci Rep. 2019 Aug 28;9(1):12483
pubmed: 31462719
Eur Radiol Exp. 2020 Feb 7;4(1):11
pubmed: 32034573
Acta Oncol. 2010 Oct;49(7):1012-6
pubmed: 20831489
J Imaging. 2022 Feb 15;8(2):
pubmed: 35200748
Clin Imaging. 2021 Jan;69:82-90
pubmed: 32693228
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1308-1318
pubmed: 29891201
Hell J Nucl Med. 2017 Sep-Dec;20 Suppl:80-92
pubmed: 29324917
Phys Imaging Radiat Oncol. 2021 Feb 11;17:100-105
pubmed: 33898787
J Nucl Med. 2013 Apr;54(4):532-40
pubmed: 23345303
Sci Rep. 2015 Aug 05;5:11075
pubmed: 26242464
Clin Transl Radiat Oncol. 2021 Mar 12;28:62-70
pubmed: 33778174
JAMA Oncol. 2017 Nov 01;3(11):1487-1494
pubmed: 28542679
Methods. 2021 Apr;188:20-29
pubmed: 32504782
Acta Oncol. 2022 Jan;61(1):73-80
pubmed: 34632924
Radiother Oncol. 2019 Jan;130:2-9
pubmed: 30416044
Cancers (Basel). 2022 Jul 22;14(15):
pubmed: 35892831
Int J Mol Sci. 2021 May 28;22(11):
pubmed: 34071702
Front Oncol. 2022 Apr 22;12:824509
pubmed: 35530350
Med Phys. 2019 Feb;46(2):665-678
pubmed: 30506687
J Nucl Med. 2018 Aug;59(8):1321-1328
pubmed: 29301932
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929
Quant Imaging Med Surg. 2019 Jul;9(7):1288-1302
pubmed: 31448214

Auteurs

David C Marcu (DC)

Faculty of Electrical Engineering & Information Technology, University of Oradea, 410087 Oradea, Romania.

Cristian Grava (C)

Faculty of Electrical Engineering & Information Technology, University of Oradea, 410087 Oradea, Romania.

Loredana G Marcu (LG)

Faculty of Informatics & Science, University of Oradea, 410087 Oradea, Romania.
Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH